Literature DB >> 9625434

Synthesis, characterization and nitric oxide release profile of nitrosylcobalamin: a potential chemotherapeutic agent.

J A Bauer1.   

Abstract

Nitrosylcobalamin, a vitamin B12-based, non-toxic carrier of nitric oxide (NO), has been synthesized, isolated and characterized in vitro. A UV/Vis analysis was performed confirming the reduction of the cobalt atom of hydroxocobalamin (vitamin B12a) with the binding of NO, causing a shift in the absorption spectra of CO3+ (lambdamax=530) to CO2+ (lambdamax=500) with the formation of nitrosylcobalamin. The extinction coefficient (epsilonmax) of nitrosylcobalamin, as calculated, was 4.8 (mM(-1), cm(-1)). An IR analysis determined the v(NO) vibrational frequency at 1652 cm(-1), supporting the binding of NO and suggesting a bent bonding geometry. NO release was maximized utilizing acidic conditions (pH 4.9, 32 degrees C) with a cumulative release of about 4610 nmol of NO in 675 h (calculated half-life of 210 h), representing 39% NO loading based on 11,890 nmol NO, theoretically possible (one NO per molecule of hydroxocobalamin). The cumulative NO release followed first-order kinetics and was pH dependent. NO release was minimal at pH 6.0 and 7.4 (37 degrees C), and undetected at pH 10 (37 degrees C). The possibility for nitrosylcobalamin to deliver NO (the active chemotherapeutic agent) to neoplastic cells is suggested because tumor cells, specifically leukemia cells, possess surface cell receptors for vitamin B12 which is readily utilized in the cellular proliferation process. Nitrosylcobalamin may offer a 'drug targeting' approach as a potential, biologically compatible and selective chemotherapeutic agent.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9625434     DOI: 10.1097/00001813-199803000-00006

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  11 in total

1.  Immunohistochemical quantification of the vitamin B12 transport protein (TCII), cell surface receptor (TCII-R) and Ki-67 in human tumor xenografts.

Authors:  Annette M Sysel; Victor E Valli; Ray B Nagle; Joseph A Bauer
Journal:  Anticancer Res       Date:  2013-10       Impact factor: 2.480

2.  A Stability-Indicating HPLC Method for the Determination of Nitrosylcobalamin (NO-Cbl), a Novel Vitamin B12 Analog.

Authors:  Michael J Dunphy; Annette M Sysel; Joseph A Lupica; Kristie Griffith; Taylor Sherrod; Joseph A Bauer
Journal:  Chromatographia       Date:  2014-04-01       Impact factor: 2.044

3.  Reply to Sysel et al.: Comment on the importance of using nitric oxide gas in the synthesis of nitrosylcobalamin and ICH-validated methods to assess purity and stability.

Authors:  Romila Mascarenhas; Zhu Li; Carmen Gherasim; Markus Ruetz; Ruma Banerjee
Journal:  J Biol Chem       Date:  2020-10-23       Impact factor: 5.157

4.  The human B12 trafficking protein CblC processes nitrocobalamin.

Authors:  Romila Mascarenhas; Zhu Li; Carmen Gherasim; Markus Ruetz; Ruma Banerjee
Journal:  J Biol Chem       Date:  2020-05-26       Impact factor: 5.157

5.  Pharmacokinetics of intravenous nitrosylcobalamin, an antitumor agent, in healthy Beagle dogs: a pilot study.

Authors:  Annette M Sysel; Walter I Horne; Jörg M Steiner; Jan S Suchodolski; Joseph A Bauer
Journal:  Anticancer Res       Date:  2012-09       Impact factor: 2.480

6.  Nitrosylcobalamin promotes cell death via S nitrosylation of Apo2L/TRAIL receptor DR4.

Authors:  Zhuo Tang; Joseph A Bauer; Bei Morrison; Daniel J Lindner
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

7.  Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL.

Authors:  Mamta Chawla-Sarkar; Joseph A Bauer; Joseph A Lupica; Bei H Morrison; Zhuo Tang; Rhonda K Oates; Alex Almasan; Joseph A DiDonato; Ernest C Borden; Daniel J Lindner
Journal:  J Biol Chem       Date:  2003-07-24       Impact factor: 5.157

8.  Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin.

Authors:  Joseph A Bauer; Bei H Morrison; Ronald W Grane; Barbara S Jacobs; Sally Dabney; Ana M Gamero; Kevin A Carnevale; Daniel J Smith; Judith Drazba; Bellur Seetharam; Daniel J Lindner
Journal:  J Natl Cancer Inst       Date:  2002-07-03       Impact factor: 13.506

9.  Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs.

Authors:  Joseph A Bauer; Gerald Frye; Anne Bahr; Jennifer Gieg; Peter Brofman
Journal:  Invest New Drugs       Date:  2009-06-27       Impact factor: 3.850

10.  Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling.

Authors:  Joseph A Bauer; Joseph A Lupica; Heidi Schmidt; Bei H Morrison; Rebecca M Haney; Rhonda K Masci; Rebecca M Lee; Joseph A Didonato; Daniel J Lindner
Journal:  PLoS One       Date:  2007-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.